Pre-order Enquiry
Request Free Sample
Hidradenitis Suppurativa (HS) - Epidemiology Forecast to 2030
SKU ID : DEL-15560605 | Publishing Date : 01-Apr-2020 | No. of pages : 100
Request Sample
Request Customization
Check DiscountsDetailed TOC of Hidradenitis Suppurativa (HS) - Epidemiology Forecast to 2030
1. Key Insights2. Executive Summary: Hidradenitis Suppurativa (HS)
3. SWOT Analysis: Hidradenitis Suppurativa (HS)
4. Hidradenitis Suppurativa (HS) Patient Share (%) Overview at a Glance
4.1. Patient Share (%) Distribution of Hidradenitis Suppurativa in 2017 and 2030
5. Hidradenitis Suppurativa Market Overview at a Glance
5.1. Market Share (%) Distribution of Hidradenitis Suppurativa in 2017
5.2. Market Share (%) Distribution of Hidradenitis Suppurativa in 2030
6. Disease Overview: Hidradenitis Suppurativa (HS)
6.1. Introduction
6.2. Causes and Symptoms of Hidradenitis Suppurativa (HS)
6.3. Classification and Severity Assessment of Hidradenitis Suppurativa (HS)
6.3.1. Hurley Stages of HS
6.3.2. Modified Sartorius Score (MSS) of HS
6.3.3. Physician Global Assessment of Hidradenitis Suppurativa (HS-PGA)
6.3.4. Specific Severity Index of Hidradenitis Suppurativa (HSSI)
6.3.5. Pathophysiology of Hidradenitis Suppurativa
6.3.6. Genetic Basis of Hidradenitis Suppurativa (HS)
6.4. Diagnosis of Hidradenitis Suppurativa (HS)
6.4.1. Differential Diagnoses
6.4.2. Biomarkers of Hidradenitis Suppurativa (HS)
6.4.3. Risk Factors and Complications
6.4.4. Comorbidities
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Total Prevalent Patient Population of HS in the 7MM
7.4. Total Diagnosed Prevalent Patient Population of HS in the 7MM
7.5. Gender-Specific Prevalent Patient Population of HS in the 7MM
7.6. Age-Specific Prevalent Patient Population of HS in the 7MM
7.7. Stage-Specific (Severity-specific) prevalent cases of HS in the 7MM
7.8. Treated Prevalent Cases of HS in the 7MM
8. Country-wise Epidemiology of HS in the 7MM
8.1. United States
8.1.1. Total Diagnosed Prevalent cases of HS in the United States
8.1.2. Gender-Specific Prevalent cases of HS in the United States
8.1.3. Age-Specific Prevalent cases of HS in the United States
8.1.4. Stage-Specific Prevalent Cases of HS in the United States
8.1.5. Treated Prevalent Cases of HS in the United States
8.2. EU5
8.2.1. Germany
8.2.1.1. Total Diagnosed Prevalent cases of HS in Germany
8.2.1.2. Gender-Specific Prevalent cases of HS in Germany
8.2.1.3. Age-Specific Prevalent cases of HS in Germany
8.2.1.4. Stage-Specific Prevalent Cases of HS in Germany
8.2.1.5. Treated Prevalent Cases of HS in Germany
8.2.2. France
8.2.2.1. Total Diagnosed Prevalent cases of HS in France
8.2.2.2. Gender-Specific Prevalent cases of HS in France
8.2.2.3. Age-Specific Prevalent cases of HS in France
8.2.2.4. Stage-Specific Prevalent Cases of HS in France
8.2.2.5. Treated Prevalent Cases of HS in France
8.2.3. Italy
8.2.3.1. Total Diagnosed Prevalent cases of HS in Italy
8.2.3.2. Gender-Specific Prevalent cases of HS in Italy
8.2.3.3. Age-Specific Prevalent cases of HS in Italy
8.2.3.4. Stage-Specific Prevalent Cases of HS in Italy
8.2.3.5. Treated Prevalent Cases of HS in Italy
8.2.4. Spain
8.2.4.1. Total Diagnosed Prevalent cases of HS in Spain
8.2.4.2. Gender-Specific Prevalent cases of HS in Spain
8.2.4.3. Age-Specific Prevalent cases of HS in Spain
8.2.4.4. Stage-Specific Prevalent Cases of HS in Spain
8.2.4.5. Treated Prevalent Cases of HS in Spain
8.2.5. United Kingdom
8.2.5.1. Total Diagnosed Prevalent cases of HS in the United Kingdom
8.2.5.2. Gender-Specific Prevalent cases of HS in the United Kingdom
8.2.5.3. Age-Specific Prevalent cases of HS in the United Kingdom
8.2.5.4. Stage-Specific Prevalent Cases of HS in the United Kingdom
8.2.5.5. Treated Prevalent Cases of HS in the United Kingdom
8.3. Japan
8.3.1. Total Diagnosed Prevalent cases of HS in Japan
8.3.2. Gender-Specific Prevalent cases of HS in Japan
8.3.3. Age-Specific Prevalent cases of HS in Japan
8.3.4. Stage-Specific Prevalent Cases of HS in Japan
8.3.5. Treated Prevalent Cases of HS in Japan
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. Disclaimer
11. DelveInsight Capabilities
12. About DelveInsight
List of Figures, Tables and Charts Available in Hidradenitis Suppurativa (HS) - Epidemiology Forecast to 2030
Table 1 Summary of Hidradenitis Suppurativa (HS) Market, Epidemiology, and Key Events (2017–2030)Table 2 Hurley Staging System
Table 3 Modified Sartorius Score of Hidradenitis Suppurativa
Table 4 Physician Global Assessment of Hidradenitis Suppurativa (HS-PGA)
Table 5 Specific Severity Index of Hidradenitis Suppurativa (HSSI)
Table 6 Differential Diagnosis of Hidradenitis Suppurativa
Table 7 Summary of Sources Explored for the Epidemiology of HS
Table 8 Total Prevalent Cases of HS in the 7MM (2017–2030)
Table 9 Total Diagnosed Prevalent Cases of HS in the 7MM (2017–2030)
Table 10 Gender-Specific Prevalent Cases of HS in the 7MM (2017–2030)
Table 11 Age-Specific Prevalent Cases of HS in the 7MM (2017–2030)
Table 12 Stage-Specific Prevalent Cases of HS in in the 7MM (2017–2030)
Table 13 Treated Prevalent Cases of HS in the 7MM (2017–2030)
Table 14 Total Prevalent Cases of HS in the United States (2017–2030)
Table 15 Gender-Specific Prevalent Cases of HS in Germany (2017–2030)
Table 16 Age-Specific Prevalent Cases of HS in the United States (2017–2030)
Table 17 Stage-Specific Prevalent Cases of HS in the United States (2017–2030)
Table 18 Treated Prevalent Cases of HS in the United States (2017–2030)
Table 19 Total Prevalent Cases of HS in Germany (2017–2030)
Table 20 Gender-Specific Prevalent Cases of HS in Germany (2017–2030)
Table 21 Age-Specific Prevalent Cases of HS in Germany (2017–2030)
Table 22 Stage-Specific Prevalent Cases of HS in Germany 2017–2030)
Table 23 Treated Prevalent Cases of HS in Germany (2017–2030)
Table 24 Total Prevalent Cases of HS in France (2017–2030)
Table 25 Gender-Specific Prevalent Cases of HS in France (2017–2030)
Table 26 Age-Specific Prevalent Cases of HS in France (2017–2030)
Table 27 Stage-Specific Prevalent Cases of HS in France 2017–2030)
Table 28 Treated Prevalent Cases of HS in France (2017–2030)
Table 29 Total Diagnosed Prevalent Cases of HS in Italy (2017–2030)
Table 30 Gender-Specific Prevalent Cases of HS in Italy (2017–2030)
Table 31 Age-Specific Prevalent Cases of HS in Italy (2017–2030)
Table 32 Stage-Specific Prevalent Cases of HS in Italy 2017–2030)
Table 33 Treated Prevalent Cases of HS in Italy (2017–2030)
Table 34 Total Diagnosed Prevalent Cases of HS in Spain (2017–2030)
Table 35 Gender-Specific Prevalent Cases of HS in Spain (2017–2030)
Table 36 Age-Specific Prevalent Cases of HS in Spain (2017–2030)
Table 37 Stage-Specific Prevalent Cases of HS in Spain (2017–2030)
Table 38 Treated Prevalent Cases of HS in Spain (2017–2030)
Table 39 Total Diagnosed Prevalent Cases of HS in the United Kingdom (2017–2030)
Table 40 Gender-Specific Prevalent Cases of HS in the United Kingdom (2017–2030)
Table 41 Age-Specific Prevalent Cases of HS in the United Kingdom (2017–2030)
Table 42 Stage-Specific Prevalent Cases of HS in the United Kingdom 2017–2030)
Table 43 Treated Prevalent Cases of HS in the United Kingdom (2017–2030)
Table 44 Total Diagnosed Prevalent Cases of HS in Japan (2017–2030)
Table 45 Gender-Specific Prevalent Cases of HS in Japan (2017–2030)
Table 46 Age-Specific Prevalent Cases of HS in Japan (2017–2030)
Table 47 Stage-Specific Prevalent Cases of HS in Japan 2017–2030)
Table 48 Treated Prevalent Cases of HS in Japan (2017–2030)
Figure 1 Hidradenitis Suppurativa (HS) SWOT Analysis
Figure 2 Disease Burden in the Patient with HS
Figure 3 Stages of Hidradenitis Suppurativa
Figure 4 Pathophysiology of HS
Figure 5 An approach to the Diagnosis of Hidradenitis Suppurativa
Figure 6 Risk Factors of HS
Figure 7 Comorbidities in HS
Figure 8 Total Prevalent Cases of HS in the 7MM (2017–2030)
Figure 9 Total Diagnosed Prevalent Cases of HS in the 7MM (2017–2030)
Figure 10 Age-specific Prevalent Cases of HS in the 7MM (2017–2030)
Figure 11 Age-Specific Prevalent Cases of HS in the 7MM (2017–2030)
Figure 12 Stage-Specific Prevalent Cases of HS in in the 7MM (2017–2030)
Figure 13 Treated Prevalent Cases of HS in the 7MM (2017–2030)
Figure 14 Total Prevalent Cases of HS in the United States (2017–2030)
Figure 15 Gender-Specific Prevalent Cases of HS in the United States (2017–2030)
Figure 16 Age-Specific Prevalent Cases of HS in the United States (2017–2030)
Figure 17 Stage-Specific Prevalent cases of HS in the United States (2017–2030)
Figure 18 Treated Prevalent Cases of HS in the United States (2017–2030)
Figure 19 Total Prevalent Cases of HS in Germany (2017–2030)
Figure 20 Gender-Specific Prevalent Cases of HS in Germany (2017–2030)
Figure 21 Age-Specific Prevalent Cases of HS in Germany (2017–2030)
Figure 22 Stage-Specific Prevalent cases of HS in Germany (2017–2030)
Figure 23 Treated Prevalent Cases of HS in Germany (2017–2030)
Figure 24 Total Diagnosed Prevalent Cases of HS in France (2017–2030)
Figure 25 Gender-Specific Prevalent Cases of HS in France (2017–2030)
Figure 26 Age-Specific Prevalent Cases of HS in France (2017–2030)
Figure 27 Stage-Specific Prevalent cases of HS in France (2017–2030)
Figure 28 Treated Prevalent Cases of HS in France (2017–2030)
Figure 29 Total Diagnosed Prevalent Cases of HS in Italy (2017–2030)
Figure 30 Gender-Specific Prevalent Cases of HS in Italy (2017–2030)
Figure 31 Age-Specific Prevalent Cases of HS in Italy (2017–2030)
Figure 32 Stage-Specific Prevalent cases of HS in Italy (2017–2030)
Figure 33 Treated Prevalent Cases of HS in Italy (2017–2030)
Figure 34 Total Diagnosed Prevalent Cases of HS in Spain (2017–2030)
Figure 35 Gender-Specific Prevalent Cases of HS in Spain (2017–2030)
Figure 36 Age-Specific Prevalent Cases of HS in Spain (2017–2030)
Figure 37 Stage-Specific Prevalent cases of HS in Spain (2017–2030)
Figure 38 Treated Prevalent Cases of HS in Spain (2017–2030)
Figure 39 Total Diagnosed Prevalent Cases of HS in the United Kingdom (2017–2030)
Figure 40 Gender-Specific Prevalent Cases of HS in the United Kingdom (2017–2030)
Figure 41 Age-Specific Prevalent Cases of HS in the United Kingdom (2017–2030)
Figure 42 Stage-Specific Prevalent cases of HS in the United Kingdom (2017–2030)
Figure 43 Treated Prevalent Cases of HS in the United Kingdom (2017–2030)
Figure 44 Total Diagnosed Prevalent Cases of HS in Japan (2017–2030)
Figure 45 Gender-Specific Prevalent Cases of HS in Japan (2017–2030)
Figure 46 Age-Specific Prevalent Cases of HS in Japan (2017–2030)
Figure 47 Stage-Specific Prevalent cases of HS in Japan (2017–2030)
Figure 48 Treated Prevalent Cases of HS in Japan (2017–2030)
